SAN FRANCISCO, Calif. — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) status to pegozafermin in patients with MASH. The...
treatment News
SAN DIEGO, Calif. – SYNC-T, an investigational therapy that combines a device-induced vaccination at the tumor site with intratumoral infusion of a multitarget biologic drug led to numerous clinical responses in patients with metastatic castration-resistant prostate cancer (mCRPC), according to results reported at the American Association for Cancer Research (AACR)...
Lancaster, UK – An international team of researchers led by Lancaster University have made a promising breakthrough in the development of drugs to treat Alzheimer’s Disease. For the first time, scientists have developed a drug that works on both major aggregation-promoting ‘hotspots’ of the Tau protein in the brain –...
Toruń, Poland – Boys suffering from Barth syndrome, a genetic determined disease with a very high mortality rate, finally have hope for a cure. What has contributed to this finding is research of Dr. habil Karolina Mikulska-Ruminska, Nicolaus Copernicus University (Torun, Poland) CU Professor from the Institute of Physics. The...
BOSTON, Mass. – Tuberculosis (TB) is often overlooked in developed countries such as the United States, but this bacterial infection remains one of the deadliest diseases globally and results in millions of deaths annually. Deaths can occur even with treatment, sometimes because of drug resistance in TB bacteria and other...
Baton Rouge, Louisiana – Diabetes affects more than 1 in 10 — or more than 38 million — Americans. People with diabetes who keep their blood sugar levels in the near-normal range generally have a much lower risk of developing diabetes complications such as heart, kidney, and eye diseases. The...
Boston, Mass. – For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer. Treatment with pembrolizumab, an immunotherapy drug, after surgery significantly prolonged overall survival in patients with clear cell...
Charleston, SC – A drug that was developed to treat pancreatic cancer has now been shown to increase symptom-free survival in preclinical medulloblastoma models – all without showing signs of toxicity. Medulloblastoma is the most common malignant brain tumor in children. Survival rates vary according to which one of the...
Two biotechs are shoring up their pipelines and commercial aspirations, tacking on a clinical-stage rare disease drug and a preclinical cancer med, respectively. Fortress Biotech-founded Avenue Therapeutics is adding on a phase 1/2-stage asset from AnnJi Pharmaceutical for the treatment of spinal and bulbar muscular atrophy (SBMA). Financial details are...
MANHASSET, N.Y. — A new study led by scientists at Northwell Health’s Feinstein Institutes for Medical Research has revealed that defects in different ribosomal proteins lead to a rare blood disorder called Diamond-Blackfan Anemia Syndrome (DBAS) through surprisingly different pathways. This discovery helps explain why patients with DBAS can experience varied...